BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35043668)

  • 1. Utility of Quantitative Metrics From Dual-Layer Spectral-Detector CT for Differentiation of Pancreatic Neuroendocrine Tumor and Neuroendocrine Carcinoma.
    Wang Y; Hu X; Shi S; Song C; Wang L; Yuan J; Lin Z; Cai H; Feng ST; Luo Y
    AJR Am J Roentgenol; 2022 Jun; 218(6):999-1009. PubMed ID: 35043668
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
    Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
    Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma.
    Azoulay A; Cros J; Vullierme MP; de Mestier L; Couvelard A; Hentic O; Ruszniewski P; Sauvanet A; Vilgrain V; Ronot M
    Diagn Interv Imaging; 2020 Dec; 101(12):821-830. PubMed ID: 32709455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dual-layer spectral detector computed tomography in the diagnosis of pancreatic neuroendocrine neoplasms.
    Yuan J; Wang Y; Hu X; Shi S; Zhang N; Wang L; Deng W; Feng ST; Peng Z; Luo Y
    Eur J Radiol; 2023 Feb; 159():110660. PubMed ID: 36577182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Energy-Derived Metrics for Differentiating Adrenal Adenomas From Nonadenomas on Single-Phase Contrast-Enhanced CT.
    Loonis AT; Yu H; Glazer DI; Bay CP; Sodickson AD
    AJR Am J Roentgenol; 2023 May; 220(5):693-704. PubMed ID: 36416399
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-layer spectral detector CT: A noninvasive preoperative tool for predicting histopathological differentiation in pancreatic ductal adenocarcinoma.
    Liu W; Xie T; Chen L; Tang W; Zhang Z; Wang Y; Deng W; Xie X; Zhou Z
    Eur J Radiol; 2024 Apr; 173():111327. PubMed ID: 38330535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.
    Drljevic-Nielsen A; Donskov F; Mains JR; Andersen MB; Thorup K; Thygesen J; Rasmussen F
    AJR Am J Roentgenol; 2022 May; 218(5):867-876. PubMed ID: 34910540
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas.
    Chen HY; Pan Y; Chen JY; Liu LL; Yang YB; Li K; Yu RS; Shao GL
    Eur Radiol; 2022 Dec; 32(12):8317-8325. PubMed ID: 35759016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Quantitative Dual-Energy Computed Tomography Parameters for Differentiation of Parotid Gland Tumors.
    Wang Y; Hu H; Ban X; Jiang Y; Su Y; Yang L; Shi G; Yang L; Han R; Duan X
    Acad Radiol; 2024 May; 31(5):2027-2038. PubMed ID: 37730491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CT and MRI findings of primary hepatic neuroendocrine neoplasm].
    Li JK; Wang M; Yuan J; Song ZG
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):600-606. PubMed ID: 28835083
    [No Abstract]   [Full Text] [Related]  

  • 14. Differentiation of pancreatic neuroendocrine tumors from pancreas renal cell carcinoma metastases on CT using qualitative and quantitative features.
    van der Pol CB; Lee S; Tsai S; Larocque N; Alayed A; Williams P; Schieda N
    Abdom Radiol (NY); 2019 Mar; 44(3):992-999. PubMed ID: 30603880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical feasibility of using effective atomic number maps derived from non-contrast spectral computed tomography to identify non-calcified atherosclerotic plaques: a preliminary study.
    Chen W; Li R; Yin K; Liang J; Li H; Chen X; Sheng Z; Yu H; Mu D
    Quant Imaging Med Surg; 2022 Apr; 12(4):2280-2287. PubMed ID: 35371951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver metastases of neuroendocrine tumors: is it possible to diagnose different histologic subtypes depending on multiphasic CT features?
    Gulpinar B; Peker E; Kul M; Elhan AH; Haliloglu N
    Abdom Radiol (NY); 2019 Jun; 44(6):2147-2155. PubMed ID: 30863999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour.
    Kim DW; Kim HJ; Kim KW; Byun JH; Song KB; Kim JH; Hong SM
    Eur Radiol; 2015 May; 25(5):1375-83. PubMed ID: 25465713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.
    Karmazanovsky G; Belousova E; Schima W; Glotov A; Kalinin D; Kriger A
    Eur J Radiol; 2019 Jan; 110():66-73. PubMed ID: 30599875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rb Loss and
    Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
    Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
    [No Abstract]   [Full Text] [Related]  

  • 20. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.